LIPAC Oncology
Creating life-saving treatment options for cancer patients without the side-effects
Creating life-saving treatment options for cancer patients without the side-effects
LIPAC Oncology is a pharmaceutical company focused on advancing the development of new investigational therapies to treat intracavitary cancers. Its precision targeted liposome-bound nano-technology platform provides local delivery of taxane for the treatment of multiple tumor types. LiPax, its lead investigational candidate for the treatment of non-muscle invasive bladder cancer, is in Phase 2b development. The Company’s pipeline includes multiple orphan indications such as upper tract urothelial carcinoma, stage II/III ovarian cancer and mesothelioma.
There is no investment information
No recent news or press coverage available for LIPAC Oncology.
We care about your data, and we'd love to use cookies make your experience better.
